David-Alexandre Gros
Vermögen: 13 Mio $ am 31.05.2026
Vermögen: 13 Mio $ am 31.05.2026
Dr. David-Alexandre C.
Gros is a Chief Executive Officer & Director at Eledon Pharmaceuticals, Inc. He is on the Board of Directors at Eledon Pharmaceuticals, Inc. Dr. Gros was previously employed as a Chairman & Chief Executive Officer by Sabeton SA, a Chairman & Chief Executive Officer by Imbria Pharmaceuticals, Inc., a President, Chief Operating & Financial Officer by Neurocrine Biosciences, Inc., a Chief Financial Officer by Alnylam Pharmaceuticals, Inc., a Member-Supervisory Board by Sabeton SA, a Chief Strategy Officer & Executive Vice President by Sanofi, a Chief Strategy Officer by Sanofi, a Principal by Centerview Partners LLC, and an Associate Principal by McKinsey & Co., Inc. He also served on the board at Eliem Therapeutics, Inc. He received his undergraduate degree from Dartmouth College, an MBA from Harvard Business School and a doctorate degree from The Johns Hopkins University School of Medicine.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SAINT JEAN GROUPE SA 15,62 % | 07.05.2026 | 500 000 ( 15,62 % ) | 13 Mio $ | 31.05.2026 |
| 31.03.2026 | 9 000 ( 0,01 % ) | 34 290 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ELEDON PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 09.09.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
| SAINT JEAN GROUPE | Vorstandsvorsitzender | 30.06.2026 |
| CLIMB BIO, INC. | Gründer | 01.10.2020 |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Vorstandsvorsitzender | 01.09.2020 |
| NEUROCRINE BIOSCIENCES, INC. | Präsident | 31.12.2017 |
| ALNYLAM PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 06.01.2017 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Dartmouth College
Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Saint Jean Groupe SA
Saint Jean Groupe SA Food: Major DiversifiedConsumer Non-Durables Operates as an investment holding company with the interest in agro foods sector | Consumer Non-Durables |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Centerview Partners LLC
Centerview Partners LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Johns Hopkins University School of Medicine
The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Commercial Services |
Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen